Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva reports negative final results for ALS drug

Teva reports negative final results for ALS drug

14th March 2008

Teva has reported that its candidate glatiramer acetate (GA) 40 mg was found to be safe and well-tolerated in patients with amyotrophic lateral sclerosis (ALS) but that the study did not meet its primary endpoint.

The pharmaceutical company announced the final results of its global phase II trial which was intended to assess the safety, tolerability and efficacy of GA 40 mg administered once-daily as a subcutaneous injection for the reduction in disease-related functional deterioration in ALS patients.

Results demonstrated that GA 40 mg did not meet the study’s primary and secondary endpoints despite being shown to be safe and well-tolerated in ALS patients.

Professor Vincent Meininger, from the Hospital de la Salpetriere in Paris and the study lead investigator, acknowledged that the drug candidate did not “prove beneficial” for ALS patients.

However, he added: “The academic community caring for ALS patients is very pleased with Teva’s commitment to continue developing innovative treatment options such as Talampanel for such a devastating disease”.

Last month, following the release of fourth-quarter and full-year 2007 financial results, Teva Pharmaceutical’s president and chief executive officer Shlomo Yanai described 2007 as an “outstanding year”.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.